Silence Therapeutics Reports Results From Ongoing SANRECO Phase 1 Repeat Dose Study Of Divesiran; Says Data Support Advancing Divesiran Into Phase 2
Portfolio Pulse from Benzinga Newsdesk
Silence Therapeutics reports positive results from the ongoing SANRECO Phase 1 repeat dose study of Divesiran, indicating the drug is well tolerated with no major safety issues. The data supports advancing Divesiran into Phase 2 trials.
June 27, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silence Therapeutics' Divesiran has shown positive results in the Phase 1 study, with no major safety issues, supporting its advancement to Phase 2 trials.
The positive Phase 1 results and the absence of major safety issues are likely to boost investor confidence and support the stock price in the short term as the drug advances to Phase 2 trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100